-
10:43:04 AM

CLVS - Clovis Oncology Inc

12/21/20 8:00 AM
Nasdaq : CLVS
Clovis Oncology's Rubraca(R) (rucaparib) Met the Primary Endpoint of Significantly Improving Progression-Free Survival vs. Chemotherapy in the ARIEL4 Randomized Phase 3 Treatment Study in Later-line Ovarian Cancer Patients with a BRCA mutation
Clovis Oncology, Inc. (NASDAQ: CLVS), today announced topline data from the randomized Phase 3 ARIEL4 study of Rubraca, which met its primary endpoint of improved investigator-assessed progression-free survival (InvPFS) compared to chemotherapy in relapsed ovarian cancer patients with a tumor
RHEA-AI
neutral
11/05/20 8:05 AM
Nasdaq : CLVS
Clovis Oncology Announces Third Quarter 2020 Operating Results
Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter ended September 30, 2020, and provided an update on the Company's clinical development programs and regulatory and commercial outlook for the rest of the year. "We are pleased that third quarter revenues for Rubraca grew slightly over the same period in 2019, despite a very challenging sales environment caused by COVID-19, which has severely limited oncology patient visits and cancer
RHEA-AI
positive